These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 826650)
1. Combined-modality oncotherapy with cyclophosphamide (NSC-26271) and radiotherapy: control of murine mastocytoma. Schenken LL; Hagemann RF; Burholt DR; Lesher S J Natl Cancer Inst; 1976 Oct; 57(4):943-9. PubMed ID: 826650 [TBL] [Abstract][Full Text] [Related]
2. Responses of an experimental solid tumour to irradiation: A comparison of modes of fractionation. Schenken LL; Poulakos L; Hagemann RF Br J Cancer; 1975 Feb; 31(2):228-36. PubMed ID: 809050 [TBL] [Abstract][Full Text] [Related]
3. Control of local tumor growth with combined fractionated radiotherapeutic and chemotherapeutic regimens. Poulakos L; Schenken LL; Hagemann RF; Burholt DR; Lesher S J Natl Cancer Inst; 1975 May; 54(5):1103-5. PubMed ID: 805253 [TBL] [Abstract][Full Text] [Related]
4. Treatment of solid P815x2 murine mastocytoma with adriamycin (NSC-1231127): toxity limitations. Schenken LL; Poulakos L; Hagemann RF; Burholt D; Lesher S J Natl Cancer Inst; 1976 Mar; 56(3):683-5. PubMed ID: 815561 [TBL] [Abstract][Full Text] [Related]
5. Relationship of tumor regrowth to tumor cell survival, tumor cure rates and host survival in a solid tumor model following combined chemotherapy and radiotherapy. Hopkins HA; Looney WB; Carter WH; Reto DC; Campbell ED In Vivo; 1994; 8(1):97-105. PubMed ID: 8054518 [TBL] [Abstract][Full Text] [Related]
6. [The synergistic action of lipopolysaccharide and muramyl dipeptide in the immunotherapy of DBA/2 mice with mastocytoma P815]. Rakhmilevich AL; Rakhimova MS Biull Eksp Biol Med; 1989 Dec; 108(12):721-4. PubMed ID: 2517487 [TBL] [Abstract][Full Text] [Related]
7. Multiple drug chemotherapy combined with multiple fractions per day (MFD) radiotherapy in an experimental solid tumor model. Hopkins HA; Looney WB; Carter WH; Reto DC; Campbell ED In Vivo; 1994; 8(1):107-12. PubMed ID: 8054501 [TBL] [Abstract][Full Text] [Related]
8. Proliferative character and growth modes of neoplastic disease as determinants of chemotherapeutic efficacy. Schenken LL Cancer Treat Rep; 1976 Dec; 60(12):1761-76. PubMed ID: 829040 [No Abstract] [Full Text] [Related]
9. Dynamics of tumor cell clonogen repopulation in a murine sarcoma treated with cyclophosphamide. Milas L; Nakayama T; Hunter N; Jones S; Lin TM; Yamada S; Thames H; Peters L Radiother Oncol; 1994 Mar; 30(3):247-53. PubMed ID: 8209009 [TBL] [Abstract][Full Text] [Related]
10. Therapy of the murine plasmacytoma MOPC 104E: role of the immune response. Lubet RA; Carlson DE J Natl Cancer Inst; 1978 Sep; 61(3):897-903. PubMed ID: 278867 [TBL] [Abstract][Full Text] [Related]
11. [Regression of mastocytoma in mice following virus treatment]. Bandlow G; Schlemminger B; Bandlow K Verh Dtsch Ges Inn Med; 1974; 80():1668-70. PubMed ID: 4217987 [No Abstract] [Full Text] [Related]
12. Survival of mice with metastatic osteosarcoma treated by cyclophosphamide or radiotherapy. Shaeffer J; El-Mahdi AM; Constable WC Cancer Res; 1975 Dec; 35(12):3596-8. PubMed ID: 1059504 [TBL] [Abstract][Full Text] [Related]
14. Solid tumor models for the assessment of different treatment modalities. XIX. Tumor cure rates and tumor control following sequential administration of radiation and cyclophosphamide. Looney WB; Ritenour ER; Hopkins HA Am J Clin Oncol; 1982 Apr; 5(2):209-20. PubMed ID: 7091043 [TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors. Corbett TH; Griswold DP; Mayo JG; Laster WR; Schabel FM Cancer Res; 1975 Jun; 35(6):1568-73. PubMed ID: 1131824 [TBL] [Abstract][Full Text] [Related]
16. Urinary excretion of 5-hydroxyindoles as an indicator of in vivo growth of P815X2 mastocytoma. Raikow RB; Schenken LL; Lesher S Eur J Cancer (1965); 1976 Dec; 12(12):1011-5. PubMed ID: 827448 [No Abstract] [Full Text] [Related]
17. Corynebacterium parvum and cyclophosphamide as combination treatment for a murine mammary adenocarcinoma. Purnell DM; Bartlett GL; Kreider JW; Biro TG Cancer Res; 1977 Apr; 37(4):1137-40. PubMed ID: 844041 [TBL] [Abstract][Full Text] [Related]
18. Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors. Nitta K; Tanaka T; Takeuchi M Cancer Treat Rep; 1985 Mar; 69(3):285-91. PubMed ID: 3978657 [TBL] [Abstract][Full Text] [Related]
19. Effects of the antiestrogen EM-800 (SCH 57050) and cyclophosphamide alone and in combination on growth of human ZR-75-1 breast cancer xenografts in nude mice. Gutman M; Couillard S; Labrie F; Candas B; Labrie C Cancer Res; 1999 Oct; 59(20):5176-80. PubMed ID: 10537294 [TBL] [Abstract][Full Text] [Related]
20. Solid tumor models for the assessment of different treatment modalities. XXI. Comparison of different radiation dose schedules alone or in combination with cyclophosphamide. Looney WB; Longerbeam MB; Hopkins HA; Carter WH Cancer; 1983 Mar; 51(6):1012-20. PubMed ID: 6821865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]